Loading…
Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting
Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help r...
Saved in:
| Published in: | Advanced drug delivery reviews 2019-02, Vol.140, p.129-135 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863 |
| container_end_page | 135 |
| container_issue | |
| container_start_page | 129 |
| container_title | Advanced drug delivery reviews |
| container_volume | 140 |
| creator | Fabre, Kristin M. Delsing, Louise Hicks, Ryan Colclough, Nicola Crowther, Damian C. Ewart, Lorna |
| description | Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics.
[Display omitted] |
| doi_str_mv | 10.1016/j.addr.2018.09.009 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_gup_ub_gu_se_283679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X1830245X</els_id><sourcerecordid>2112613500</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEokPhBVggL1mQ4EvsJIhNVcpFqsSGInaWL2cyHiVxsB3Q8EJ9TRxSuoOVpePv_22dryieE1wRTMTrY6WsDRXFpK1wV2HcPSh2pG1o2dKufljsMtSVNe6-nRVPYjxiTGgj8OPijGHKWc7titub5Ab3y009Gp0Jfj6covOD751RA4qnmGCMSE0WuckuBiyahyW42SeYElpvkYFhiGjvA7IugoqARm9hyJVvkEJmHcS02NMfRA_eW6SDchPSKgQHAQXIsWAO-YkcmA8qjMrAkrYvQEq56mnxaK-GCM_uzvPi5v3Vl8uP5fXnD58uL65LUzOSSl4LoXijG80NqwGU4ACm3neMi71Q2giBuaVGcU0Ipg3XFgtGCbQ1WNwKdl6UW2_8CfOi5RzcqMJJeuVkv8wyj_pFRpC0ZaLpMv_qn_w79_VC-tDLg4uSCIZ5xl9u-Bz89wVikqOL6wLVBH6JkhJCBWEc44zSDc1WYgywv-8mWK7-5VGu_uXqX-JOZv859OKuf9Ej2PvIX-EZeLsBkJf4I29fRuNgymJdAJOk9e5__b8BooLGhA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112613500</pqid></control><display><type>article</type><title>Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting</title><source>ScienceDirect Freedom Collection</source><creator>Fabre, Kristin M. ; Delsing, Louise ; Hicks, Ryan ; Colclough, Nicola ; Crowther, Damian C. ; Ewart, Lorna</creator><creatorcontrib>Fabre, Kristin M. ; Delsing, Louise ; Hicks, Ryan ; Colclough, Nicola ; Crowther, Damian C. ; Ewart, Lorna</creatorcontrib><description>Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics.
[Display omitted]</description><identifier>ISSN: 0169-409X</identifier><identifier>ISSN: 1872-8294</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2018.09.009</identifier><identifier>PMID: 30253201</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Bioinformatics ; Bioinformatik ; Blood ; Blood brain barrier ; cns ; crispr/cas9 ; differentiation ; Drug development ; Drug Discovery ; Drug products ; efficient generation ; endothelial-cells ; Farmaceutiska vetenskaper ; Humans ; in-vitro model ; Induced Pluripotent Stem Cells ; INF502 Biomarkers ; INF502 Biomarkörer ; inflammation ; iPSC ; Microphysiological systems ; Models, Biological ; Neurodegenerative diseases ; On chips ; Organs-on-chips ; penetration ; permeability ; Pharmaceutical ; Pharmaceutical company ; Pharmaceutical industry ; Pharmaceutical Sciences ; Pharmacology & Pharmacy ; Physiological models ; Physiological response ; Stem cells ; Tissue chips ; Translational Medical Research</subject><ispartof>Advanced drug delivery reviews, 2019-02, Vol.140, p.129-135</ispartof><rights>2018</rights><rights>Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863</citedby><cites>FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30253201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-16305$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/283679$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabre, Kristin M.</creatorcontrib><creatorcontrib>Delsing, Louise</creatorcontrib><creatorcontrib>Hicks, Ryan</creatorcontrib><creatorcontrib>Colclough, Nicola</creatorcontrib><creatorcontrib>Crowther, Damian C.</creatorcontrib><creatorcontrib>Ewart, Lorna</creatorcontrib><title>Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics.
[Display omitted]</description><subject>Animals</subject><subject>Bioinformatics</subject><subject>Bioinformatik</subject><subject>Blood</subject><subject>Blood brain barrier</subject><subject>cns</subject><subject>crispr/cas9</subject><subject>differentiation</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Drug products</subject><subject>efficient generation</subject><subject>endothelial-cells</subject><subject>Farmaceutiska vetenskaper</subject><subject>Humans</subject><subject>in-vitro model</subject><subject>Induced Pluripotent Stem Cells</subject><subject>INF502 Biomarkers</subject><subject>INF502 Biomarkörer</subject><subject>inflammation</subject><subject>iPSC</subject><subject>Microphysiological systems</subject><subject>Models, Biological</subject><subject>Neurodegenerative diseases</subject><subject>On chips</subject><subject>Organs-on-chips</subject><subject>penetration</subject><subject>permeability</subject><subject>Pharmaceutical</subject><subject>Pharmaceutical company</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceutical Sciences</subject><subject>Pharmacology & Pharmacy</subject><subject>Physiological models</subject><subject>Physiological response</subject><subject>Stem cells</subject><subject>Tissue chips</subject><subject>Translational Medical Research</subject><issn>0169-409X</issn><issn>1872-8294</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1DAUhiMEokPhBVggL1mQ4EvsJIhNVcpFqsSGInaWL2cyHiVxsB3Q8EJ9TRxSuoOVpePv_22dryieE1wRTMTrY6WsDRXFpK1wV2HcPSh2pG1o2dKufljsMtSVNe6-nRVPYjxiTGgj8OPijGHKWc7titub5Ab3y009Gp0Jfj6covOD751RA4qnmGCMSE0WuckuBiyahyW42SeYElpvkYFhiGjvA7IugoqARm9hyJVvkEJmHcS02NMfRA_eW6SDchPSKgQHAQXIsWAO-YkcmA8qjMrAkrYvQEq56mnxaK-GCM_uzvPi5v3Vl8uP5fXnD58uL65LUzOSSl4LoXijG80NqwGU4ACm3neMi71Q2giBuaVGcU0Ipg3XFgtGCbQ1WNwKdl6UW2_8CfOi5RzcqMJJeuVkv8wyj_pFRpC0ZaLpMv_qn_w79_VC-tDLg4uSCIZ5xl9u-Bz89wVikqOL6wLVBH6JkhJCBWEc44zSDc1WYgywv-8mWK7-5VGu_uXqX-JOZv859OKuf9Ej2PvIX-EZeLsBkJf4I29fRuNgymJdAJOk9e5__b8BooLGhA</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Fabre, Kristin M.</creator><creator>Delsing, Louise</creator><creator>Hicks, Ryan</creator><creator>Colclough, Nicola</creator><creator>Crowther, Damian C.</creator><creator>Ewart, Lorna</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF6</scope><scope>F1U</scope></search><sort><creationdate>20190201</creationdate><title>Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting</title><author>Fabre, Kristin M. ; Delsing, Louise ; Hicks, Ryan ; Colclough, Nicola ; Crowther, Damian C. ; Ewart, Lorna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Bioinformatics</topic><topic>Bioinformatik</topic><topic>Blood</topic><topic>Blood brain barrier</topic><topic>cns</topic><topic>crispr/cas9</topic><topic>differentiation</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Drug products</topic><topic>efficient generation</topic><topic>endothelial-cells</topic><topic>Farmaceutiska vetenskaper</topic><topic>Humans</topic><topic>in-vitro model</topic><topic>Induced Pluripotent Stem Cells</topic><topic>INF502 Biomarkers</topic><topic>INF502 Biomarkörer</topic><topic>inflammation</topic><topic>iPSC</topic><topic>Microphysiological systems</topic><topic>Models, Biological</topic><topic>Neurodegenerative diseases</topic><topic>On chips</topic><topic>Organs-on-chips</topic><topic>penetration</topic><topic>permeability</topic><topic>Pharmaceutical</topic><topic>Pharmaceutical company</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceutical Sciences</topic><topic>Pharmacology & Pharmacy</topic><topic>Physiological models</topic><topic>Physiological response</topic><topic>Stem cells</topic><topic>Tissue chips</topic><topic>Translational Medical Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabre, Kristin M.</creatorcontrib><creatorcontrib>Delsing, Louise</creatorcontrib><creatorcontrib>Hicks, Ryan</creatorcontrib><creatorcontrib>Colclough, Nicola</creatorcontrib><creatorcontrib>Crowther, Damian C.</creatorcontrib><creatorcontrib>Ewart, Lorna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Högskolan i Skövde</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabre, Kristin M.</au><au>Delsing, Louise</au><au>Hicks, Ryan</au><au>Colclough, Nicola</au><au>Crowther, Damian C.</au><au>Ewart, Lorna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>140</volume><spage>129</spage><epage>135</epage><pages>129-135</pages><issn>0169-409X</issn><issn>1872-8294</issn><eissn>1872-8294</eissn><abstract>Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30253201</pmid><doi>10.1016/j.addr.2018.09.009</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-409X |
| ispartof | Advanced drug delivery reviews, 2019-02, Vol.140, p.129-135 |
| issn | 0169-409X 1872-8294 1872-8294 |
| language | eng |
| recordid | cdi_swepub_primary_oai_gup_ub_gu_se_283679 |
| source | ScienceDirect Freedom Collection |
| subjects | Animals Bioinformatics Bioinformatik Blood Blood brain barrier cns crispr/cas9 differentiation Drug development Drug Discovery Drug products efficient generation endothelial-cells Farmaceutiska vetenskaper Humans in-vitro model Induced Pluripotent Stem Cells INF502 Biomarkers INF502 Biomarkörer inflammation iPSC Microphysiological systems Models, Biological Neurodegenerative diseases On chips Organs-on-chips penetration permeability Pharmaceutical Pharmaceutical company Pharmaceutical industry Pharmaceutical Sciences Pharmacology & Pharmacy Physiological models Physiological response Stem cells Tissue chips Translational Medical Research |
| title | Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A42%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utilizing%20microphysiological%20systems%20and%20induced%20pluripotent%20stem%20cells%20for%20disease%20modeling:%20a%20case%20study%20for%20blood%20brain%20barrier%20research%20in%20a%20pharmaceutical%20setting&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Fabre,%20Kristin%20M.&rft.date=2019-02-01&rft.volume=140&rft.spage=129&rft.epage=135&rft.pages=129-135&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2018.09.009&rft_dat=%3Cproquest_swepu%3E2112613500%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c431t-5466a57b7b5c34eea65eec4f9356f6abc6605d2ca5b110275bd06321e84ed0863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2112613500&rft_id=info:pmid/30253201&rfr_iscdi=true |